Wenqiang Li

Dr. Wenqiang Li


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2024 in Medicine
Verified
Journal Article
Open access
NYNan Yao
Nan Yao
WLWenqiang Li
Wenqiang Li
NDNing Duan
Ning Duan
GXGuoshuai Xu
Guoshuai Xu
GYGuoyong Yu
Guoyong Yu
Jun QuJun Qu
Jun Qu
Gastrointestinal (GI) cancers pose a significant challenge due to high prevalence and mortality. While advancements in detection and conventional treatments have been made, prognosis often remains poor, particularly for advanced-stage cancers. Immunotherapy has emerged as a transformative approach, leveraging the body immune system against cancer, including immune checkpoint inhibitors (ICIs), cancer vaccines, and adoptive cell transfer. These modalities have shown promise, achieving sustained responses and improved survival in some patients. However, their efficacy in GI cancers is less pronounced, hindered by drug resistance mechanisms that are either intrinsic or acquired over time. This review examines the latest understanding of immunotherapy in GI cancers, focusing on ICIs, cancer vaccines, and adoptive cell transfer, along with their associated outcomes and limitations. It delves into the mechanisms behind drug resistance, including alterations in immune checkpoints, the immunosuppressive tumor microenvironment, and genetic/epigenetic changes. The role of the gut microbiome is also considered as an emerging factor in resistance. To combat drug resistance, strategies such as enhancing immune response, targeting the tumor microenvironment, and modulating resistance mechanisms are explored. The review underscores the potential of ferroptosis induction as a novel approach. Looking forward, it highlights the need for personalized immunotherapies, understanding the influence of the gut microbiome, and further exploration of ferroptosis in overcoming resistance. While challenges persist, the continuous evolution in GI cancer immunotherapy research promises innovative treatments that could significantly improve patient outcomes.

5 January 2024 in Medicine
Verified
Journal Article
Open access
YZYin Zhang
Yin Zhang
JWJiaying Mm Wang
Jiaying Mm Wang
MZMingyu Mm Zheng
Mingyu Mm Zheng
HQHuanwei Qu
Huanwei Qu
SYShuya Mm Yang
Shuya Mm Yang
Jun QuJun Qu
Jun Qu
We performed a bidirectional 2-sample Mendelian randomization (MR) design to explore the causal relation between telomere length (TL) and colorectal polyps. Genome-wide association study summary data of TL and colorectal polyps were extracted from the IEU open genome-wide association study database. Single nucleotide polymorphisms were served as instrumental variables at the significance threshold of P < 5 × 10−8. The inverse variance weighted method, MR-Egger method, and weight median method were performed for causal estimation in MR. Cochran Q test, MR-Egger intercept test, and leave-one-out analyses were performed to evaluate the pleiotropy of the MR results. One hundred and twenty-four single nucleotide polymorphisms were selected as instrumental variables. We found significant casual association between TL and colorectal polyps. Long TL increased the risk of colorectal polyps using the inverse variance weighted method [ukb-a-521: odds ratio (OR): 1.004, 95% confidence interval (CI): 1.001–1.007, P = .004; ukb-d-D12: OR: 1.008, CI: 1.004–1.012, P < .001; finn-b-CD2_BENIGN_COLORECANI_EXALLC2: OR: 1.170, CI: 1.027–1.332, P = .018]. Sensitivity analyses validated that the causality between TL and colorectal polyps was robust. The study provided a causal association between TL and colorectal polyps which indicated that TL might be served as a potential biomarker of colorectal polyps for screening and prevention. Nonetheless, the conclusions need further validation.

11 July 2025 in Medicine
Verified
Journal Article
Open access
TQTianqi Qi
Tianqi Qi
YWYingshi Mm Wang
Yingshi Mm Wang
YLYanhui Mm Liu
Yanhui Mm Liu
WLWenqiang Li
Wenqiang Li
SWShanshan Wu
Shanshan Wu
Rationale: Bacillus licheniformis and Lactiplantibacillus plantarum are facultative anaerobes and gram-positive bacteria. They are commonly included in probiotic preparations and are administered orally in clinical practice to promote a balanced gut microbiota. Patient concerns: An 85-year-old man with irritable bowel syndrome and reflux esophagitis underwent distal pancreatectomy and was administered oral probiotics. Blood culture was positive for B. licheniformis and L. plantarum. We conducted whole-genome sequencing for homology analysis and pathogenicity prediction of the strains isolated from the patient’s blood culture and oral probiotics. Diagnosis: The initial diagnosis was bacterial entry into the bloodstream resulting from the consumption of B. licheniformis and L. plantarum probiotic preparations. Interventions: The patient was treated with discontinuation of oral probiotics and timely administration of antibiotics. Outcomes: Follow-up blood culture results after treatment were negative. Lessons: Probiotics are generally considered relatively safe but should be preceded by risk screening in vulnerable populations. Whole-genome sequencing revealed the potential risks of probiotic use through homology analysis and prediction of virulence factors and antibiotic resistance.

24 November 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
YZYin Zhang
Yin Zhang
FHFuzhou Han
Fuzhou Han
MZMingyu Zheng
Mingyu Zheng
DXDuo Xu
Duo Xu
NYNan Yao
Nan Yao
Jun QuJun Qu
Jun Qu
Background For patients with early-onset T1 colorectal cancer (CRC), it is crucial to perform radical resection with minimal tissue damage. This study aims to develop and elucidate a machine learning model for the identification of non-located early-onset T1 CRC. Methods We extracted relevant data from the Surveillance, Epidemiology, and End Results (SEER) database and randomly allocated patients into a training set and a validation set. Five machine learning models were utilized: extreme gradient boosting (XGBoost), support vector machine (SVM), random forest (RF), decision tree (DT), and logistic regression (LR) were developed for the tumor metastasis status prediction. Area under the receiver operating characteristic curve (AUC) and confusion matrix were used to evaluate the model. The Shapley Additive Explanations (SHAP) method was employed as the primary technique for model explanation. Results A cohort of 1,878 patients was selected according to predefined inclusion and exclusion criteria. The XGBoost model was selected for its favorable performance, with an AUC of 0.755 and accuracy of 0.833 in the validation cohort. Significant risk factors, identified by SHAP values greater than 0.1 for non-localized T1 tumors, included carcinoembryonic antigen (CEA) levels exceeding 5 ng/mL, tumor size greater than 5 cm, mucinous adenocarcinoma, signet-ring cell adenocarcinoma, tumor location in the left colon, and poorly differentiated or undifferentiated histological grades. Additionally, black race, a diagnostic-to-surgical interval exceeding one month and PNI may represent potential risk factors. Conclusion The XGBoost model holds the potential to assist clinicians in evaluating and selecting optimal treatment strategies for patients with early-onset T1 CRC.

7 September 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
NYNan Yao
Nan Yao
NDNing Duan
Ning Duan
GXGuoshuai Xu
Guoshuai Xu
FHFuzhou Han
Fuzhou Han
WLWenqiang Li
Wenqiang Li
Jun QuJun Qu
Jun Qu
Background CLDN18.2-directed therapy has expanded biomarker-selected treatment options for gastric and gastroesophageal junction adenocarcinoma, whereas FGFR2b-directed therapy has shown clinical activity but remains investigational. Clinical interpretation depends on treatment-specific assays, thresholds, sampling quality, and the strength of evidence supporting each intervention. This review distinguishes evidence-supported clinical practice from exploratory biomarker strategies and author-proposed conceptual frameworks. Methods We synthesized clinical and translational evidence across immunotherapy-era standards of care, emphasizing trial design, diagnostic variability, intratumoral heterogeneity, treatment deliverability, and implementation barriers. Evidence was organized into three levels: prospective evidence supporting current practice, emerging clinical or translational evidence, and author-proposed hypotheses requiring prospective validation. Results SPOTLIGHT and GLOW provide randomized phase III evidence for zolbetuximab plus chemotherapy in patients selected with a treatment-specific CLDN18.2 assay and threshold. FAST and FIGHT provide supportive phase II evidence, while FORTITUDE-101 supplies phase III evidence for FGFR2b enrichment but with attenuation of the overall-survival effect at longer follow-up; FGFR2b-directed therapy therefore remains investigational. Genomic profiling, transcriptomics, multiplex immunofluorescence, digital pathology, and artificial intelligence-assisted pathology may complement IHC, but none currently replaces a validated protein-based companion diagnostic. Re-testing, dependency-first selection, cutoff engineering beyond validated criteria, and the deliverability gate remain hypothesis-generating or selectively applicable strategies rather than established standards. Conclusions Current clinical implementation should remain anchored to treatment-specific companion diagnostics, regulatory criteria, and prospective trial evidence. Complementary biomarkers and adaptive re-testing strategies are promising but require prospective validation. The dependency-first, cutoff-engineering, and deliverability frameworks are presented as research hypotheses and not as clinical recommendations.

25 August 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
NYNan Yao
Nan Yao
GXGuoshuai Xu
Guoshuai Xu
NDNing Duan
Ning Duan
FHFuzhou Han
Fuzhou Han
WLWenqiang Li
Wenqiang Li
Jun QuJun Qu
Jun Qu
Neoadjuvant immune checkpoint blockade has produced high pathological and clinical response rates in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer, raising the possibility of response-adapted organ preservation. However, the evidence is anatomically uneven and remains immature for routine surgery avoidance. In dMMR colon cancer, neoadjuvant studies primarily establish drug activity through resection-confirmed pathological and nodal response; reliable criteria for nonoperative assessment have not been validated. In dMMR rectal cancer, clinical complete response (cCR) after PD-1 blockade may support watch-and-wait in highly selected patients because local response can be reassessed using digital rectal examination, endoscopy, pelvic MRI, biopsy when appropriate, systemic imaging, and tumor markers. This narrative review critically appraises the biological rationale, prospective and observational evidence, response-assessment limitations, surgical decision points, surveillance requirements, toxicity, and unresolved controversies surrounding organ preservation after neoadjuvant immunotherapy. We use the term immune-response-adapted surgical deferral to emphasize that surgery remains available for incomplete response, unresolved uncertainty, or regrowth. Current implementation should be confined to experienced multidisciplinary programs with rigorous molecular confirmation, standardized multimodal assessment, reliable follow-up, informed patient participation, and timely salvage capacity. Particular attention is given to immunotherapy-specific uncertainty in defining durable cCR, the limitations of circulating tumor DNA (ctDNA) as a stand-alone local decision tool, hereditary-risk considerations in Lynch syndrome, and the need for location-specific prospective validation.